LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

Inicio・Lista de Acciones・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Abierto

SectorSanidad

2.7 -1.82

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.63

Máximo

2.77

Métricas clave
By Trading Economics
Ingresos	4.1M -5.7M
Empleados	34
EBITDA	3.1M -6.8M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+638.01% upside

Dividendos
By Dow Jones
Próximas Ganancias	26 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-122M 267M
Apertura anterior	4.52
Cierre anterior	2.7

Noticias sobre sentimiento de mercado

By Acuity

50%

148 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

8.275 / 9.312 Soporte y Resistencia

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 may 2026, 22:48 UTC

Adquisiciones, fusiones, absorciones

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 may 2026, 16:49 UTC

Ganancias

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 may 2026, 16:26 UTC

Principales Movimientos del Mercado

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 may 2026, 23:51 UTC

Charlas de Mercado

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 may 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 may 2026, 23:30 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 may 2026, 23:30 UTC

Charlas de Mercado

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 may 2026, 22:33 UTC

Adquisiciones, fusiones, absorciones

Conduent to Sell Public Transit Business to Modaxo for $164M

21 may 2026, 21:53 UTC

Ganancias

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 may 2026, 21:02 UTC

Ganancias

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 may 2026, 20:55 UTC

Ganancias

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 may 2026, 20:30 UTC

Acciones populares

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 may 2026, 20:20 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 may 2026, 20:20 UTC

Charlas de Mercado

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 may 2026, 20:20 UTC

Ganancias

Webull 1Q Adj EPS 3c >BULL

21 may 2026, 20:20 UTC

Ganancias

Webull 1Q Rev $159.9M >BULL

21 may 2026, 20:18 UTC

Charlas de Mercado

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 may 2026, 20:18 UTC

Ganancias

Webull 1Q Loss/Shr 4c

21 may 2026, 19:43 UTC

Charlas de Mercado

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 may 2026, 18:58 UTC

Ganancias

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 may 2026, 18:15 UTC

Charlas de Mercado

Gold Higher For Second Consecutive Day -- Market Talk

21 may 2026, 17:40 UTC

Charlas de Mercado

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 may 2026, 17:04 UTC

Charlas de Mercado

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 may 2026, 17:01 UTC

Ganancias

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 may 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Stellantis Targets Distant but Constructive -- Market Talk

21 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

638.01% repunte

Estimación a 12 Meses

Media 20 USD 638.01%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.275 / 9.312Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

148 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.